Department of Ophthalmology and Visual Science, St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea.
Cornea. 2013 Aug;32(8):1142-8. doi: 10.1097/ICO.0b013e318292a79d.
To evaluate the effect of thalidomide analogue CC-3052 on corneal neovascularization in the rabbit model.
Corneal neovascularization was induced in 15 rabbits by a silk suture in the corneal stroma. At 1 week after suturing, 30 eyes were divided into 5 groups of 6 eyes each. Three groups were treated with topical CC-3052 at 3 different concentrations: 0.25% (group 1), 0.5% (group 2), and 1.0% (group 3). All treatments were performed twice a day for a week. A 0.5% concentration of CC-3052 was injected subconjunctivally once in group 4. In group 5, a topical balanced salt solution was added twice a day for a week as the experimental control group. Rabbit corneas were photographed by a digital camera and examined by the operating microscope. Half of the corneal specimens were analyzed histopathologically, and the other half were used to measure the concentration of tumor necrosis factor α and vascular endothelial growth factor (VEGF) messenger RNA by reverse transcriptase-polymerase chain reaction.
The neovascularized area was decreased in all treatment groups compared with the control group. There was a significant difference in the percentage and score of corneal neovascularization between the control and all treatment groups. Inflammation, fibroblast, neovascularization, and anti-VEGF antibody intensities were significantly lower in the control group. The concentration of VEGF and tumor necrosis factor α was significantly lower in the control group. There was no difference between the treatment groups.
Topical and subconjunctival administration of thalidomide analogue CC-3052 was found to be effective for the inhibition of corneal neovascularization.
评估沙利度胺类似物 CC-3052 对兔角膜新生血管的作用。
通过角膜基质中的丝线缝合诱导 15 只兔子的角膜新生血管。在缝合后 1 周，将 30 只眼睛分为 5 组，每组 6 只。三组分别用三种不同浓度的 CC-3052 滴眼：0.25%（第 1 组）、0.5%（第 2 组）和 1.0%（第 3 组）。所有治疗均每天两次，持续一周。第 4 组结膜下注射 0.5%浓度的 CC-3052 一次。第 5 组作为实验组，每天滴加平衡盐溶液两次，持续一周作为实验对照组。用数码相机拍摄兔角膜照片，并用手术显微镜检查。半角膜标本进行组织病理学分析，另一半用于通过逆转录聚合酶链反应测量肿瘤坏死因子-α和血管内皮生长因子（VEGF）信使 RNA 的浓度。
与对照组相比，所有治疗组的新生血管面积均减少。对照组与所有治疗组的角膜新生血管百分比和评分均有显著差异。对照组的炎症、成纤维细胞、新生血管和抗 VEGF 抗体强度明显较低。对照组 VEGF 和肿瘤坏死因子-α的浓度明显较低。治疗组之间没有差异。
局部和结膜下给予沙利度胺类似物 CC-3052 可有效抑制角膜新生血管形成。
